PURPOSE: To describe real-world clinical characteristics, treatment patterns and outcomes of severe eosinophilic asthma (SEA) patients initiated on benralizumab after treatment authorization in Central Eastern Europe and Baltic Area. PATIENTS AND METHODS: BREEZE was a retrospective, medical chart review with a pre-post design conducted in 42 clinical centers from Bulgaria, Czech Republic, Hungary, Lithuania and Romania. Eligibility included diagnosis of SEA and at least one dose of benralizumab administered in real-life settings. Descriptive statistics were used in the full analysis set and key subgroups stratified by blood eosinophils (bEOS) number, maintenance oral corticosteroids (mOCS) use and prior biologics exposure and included calculation of the annualized exacerbation rate (AER) at baseline, and weeks (W) 16 and 48. RESULTS: Of 381 patients included, 66% were female with overall mean age 56 ±12 years at benralizumab start. At baseline: median bEOS 580 cells/μL (74% bEOS>400), forced expiratory volume in 1 second (FEV1) 1660 mL, mOCS use in 25% of patients (10 mg/day prednisone equivalent, 68% >5 mg/day), AER 3.05 (95% CI 2.9-3.2), and poorly controlled asthma (Asthma Control Test [ACT] <16) in 63% of patients. Median duration of exposure to benralizumab was 11.5 (95% CI 7.7-12.3) months, and discontinuation rate was 1.3% (95% CI 0.4%-3.0%). Median bEOS decreased to 0 at W16 and maintained thereafter; FEV1 increases of +240 mL at W16 and +335 mL at W48 were reported (p <0.001 for both). Overall relative reduction in AER at W16 and W48 was 92% and 93%, respectively, and 82-94% across key subgroups. mOCS dose reduction was 50%, and proportion of patients requiring >5 mg/day decreased constantly (25% at W16, 28% at W48). ACT scores increased from W16 to W56 (p <0.001 for all). CONCLUSION: Our findings indicate clinically meaningful benefits of benralizumab across multiple geographies and various subgroups of patients with SEA.

Department of Allergology Medical University Sofia Sofia Bulgaria

Department of Allergology National Korányi Institute for Pulmonology Budapest Hungary

Department of Pneumology 3rd Faculty of Medicine Charles University and University Hospital Bulovka Prague Czech Republic

Department of Pneumology University of Medicine and Pharmacy Carol Davila Bucharest Romania

Department of Pulmonology Lithuanian University of Health Sciences Kaunas Lithuania

Medical Affairs AstraZeneca Hungary Budapest Hungary

Medical Affairs AstraZeneca Lithuania Vilnius Lithuania

Medical Affairs AstraZeneca Romania Bucharest Romania

Zobrazit více v PubMed

Rönnebjerg L, Axelsson M, Kankaanranta H. et al. Severe asthma in a general population study: prevalence and clinical characteristics. J Asthma Allergy. 2021;14:1106–1115. doi:10.2147/JAA.S327659 PubMed DOI PMC

Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2023;43(2):343–373. doi:10.1183/09031936.00202013 PubMed DOI

Buhl R, Humbert M, Bjermer L, et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J. 2017;49(5):1700634. doi:10.1183/13993003.00634-2017 PubMed DOI

Caminati M, Bagnasco D, Vaia R, Senna G. New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic. Biol Targets Ther. 2019;13:89–95. doi:10.2147/BTT.S157183 PubMed DOI PMC

Chen S, Golam S, Myers J, Bly C, Smolen H, Xu X. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Curr Med Res Opin. 2018;34(12):2075–2088. doi:10.1080/03007995.2018.1505352 PubMed DOI

Akuthota P, Wang H, Weller PF. Eosinophils as antigen-presenting cells in allergic upper airway disease. Curr Opin Allergy Clin Immunol. 2010;10(1):14–19. doi:10.1097/ACI.0b013e328334f693 PubMed DOI PMC

Jackson DJ, Korn S, Mathur SK, et al. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: focus on Benralizumab. Drug Saf. 2020;43(5):409–425. doi:10.1007/s40264-020-00926-3 PubMed DOI PMC

Jackson DJ, Burhan H, Menzies-Gow A, et al. Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use. J Allergy Clin Immunol Pract. 2022;10(6):1534–1544.e4. doi:10.1016/j.jaip.2022.02.014 PubMed DOI

Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–1132. doi:10.1164/rccm.201103-0396OC PubMed DOI

Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled Phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-1 PubMed DOI

FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-8 PubMed DOI

Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. doi:10.1016/S2213-2600(15)00042-9 PubMed DOI

Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/nejmoa1403290 PubMed DOI

Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X PubMed DOI

Principe S, Porsbjerg C, Bolm Ditlev S, et al. Treating severe asthma: targeting the IL-5 pathway. Clin Exp Allergy. 2021;51(8):992–1005. doi:10.1111/cea.13885 PubMed DOI PMC

Dagher R, Kumar V, Copenhaver AM, et al. Novel mechanisms of action contributing to benralizumab’s potent anti-eosinophilic activity. Eur Respir J. 2022;59(3):2004306. doi:10.1183/13993003.04306-2020 PubMed DOI PMC

Bergantini L, d’Alessandro M, Pianigiani T, Cekorja B, Bargagli E, Cameli P. Benralizumab affects NK cell maturation and proliferation in severe asthmatic patients. Clin Immunol. 2023;253:109680. doi:10.1016/j.clim.2023.109680 PubMed DOI

Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017;376(25):2448–2458. doi:10.1056/nejmoa1703501 PubMed DOI

Fitzgerald JM, Bleecker ER, Bourdin A, et al. Two-year integrated efficacy and safety analysis of benralizumab in severe asthma. J Asthma Allergy. 2019;12:401–413. doi:10.2147/JAA.S227170 PubMed DOI PMC

Jackson DJ, Pelaia G, Emmanuel B, et al. Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme. Eur Respir J. 2024;64(1):2301521. doi:10.1183/13993003.01521-2023 PubMed DOI PMC

European Medicines Agency. Fasenra Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/fasenra-epar-product-information_en.pdf.

Menzella F, Bargagli E, Aliani M, et al. ChAracterization of Italian severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study. Respir Res. 2022;23(1):1–13. doi:10.1186/s12931-022-01952-8 PubMed DOI PMC

Padilla-Galo A, Moya Carmona I, Ausín P, et al. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study. Respir Res. 2023;24(1):235. doi:10.1186/s12931-023-02539-7 PubMed DOI PMC

Chaves-Loureiro C, Carrico F, Brito U, Fernandes RA, Sousa N, Mendes A. Healthcare Resource Utilization of Severe Eosinophilic Asthma Patients Treated with Benralizumab in Real-Life: results from the Portuguese BETREAT Study. In: Value in Health. ISPOR Europe. 2023;Vol. 26:S302. doi:10.1016/j.jval.2023.09.1595 DOI

Noorduyn SG, Kayaniyil S, Lancaster B, et al. Early response to benralizumab in Canadian patients with severe eosinophilic asthma: interim results from a prospective observational cohort. Can J Respir Crit Care, Sleep Med. 2024;8(3):99–107. doi:10.1080/24745332.2024.2339195 DOI

Schleich F, Moermans C, Seidel L, et al. Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction – PROMISE. ERJ Open Res. 2023;9(6):00383–2023. doi:10.1183/23120541.00383-2023 PubMed DOI PMC

Carstens D, Maselli DJ, Mu F, et al. Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2. J Allergy Clin Immunol Pract. 2023;11(7):2150–2161.e4. doi:10.1016/j.jaip.2023.04.029 PubMed DOI

Chan R, RuiWen Kuo C, Jabbal S, Lipworth BJ. Eosinophil depletion with benralizumab is associated with attenuated mannitol airway hyperresponsiveness in severe uncontrolled eosinophilic asthma. J Allergy Clin Immunol. 2023;151(3):700–705.e10. doi:10.1016/j.jaci.2022.10.028 PubMed DOI

Pini L, Bagnasco D, Beghè B, et al. Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: a Three-Year Real-Life Study. J Clin Med. 2024;13(10):3013. doi:10.3390/jcm13103013 PubMed DOI PMC

Pelaia C, Crimi C, Benfante A, et al. Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: real-life evaluation correlated with allergic and non-allergic phenotype expression. J Asthma Allergy. 2021;14:163–173. doi:10.2147/JAA.S297273 PubMed DOI PMC

Vultaggio A, Aliani M, Altieri E, et al. Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study. Respir Res. 2023;24(1):1–13. doi:10.1186/s12931-023-02439-w PubMed DOI PMC

Korn S, Bourdin A, Chupp G, et al. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years. J Allergy Clin Immunol Pract. 2021;9(12):4381–4392.e4. doi:10.1016/j.jaip.2021.07.058 PubMed DOI

Yamaguchi M, Nishimura Y, Takumi Y, Hayashi N, Sakamoto K, Tohda Y. Real-World Safety and Effectiveness of Benralizumab in Japanese Patients with Severe Asthma: a Multicenter Prospective Observational Study. J Asthma Allergy. 2024;17(January):45–60. doi:10.2147/JAA.S432695 PubMed DOI PMC

Chan R, Misirovs R, Lipworth B. Repeatability of impulse oscillometry in patients with severe asthma. Eur Respir J. 2022;59(1):10–13. doi:10.1183/13993003.01679-2021 PubMed DOI

Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757–765. doi:10.1016/j.jaci.2019.12.006 PubMed DOI

Blaiss M, Oppenheimer J, Corbett M, et al. Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment. Ann Allergy Asthma Immunol. 2023;131(6):782–785. doi:10.1016/j.anai.2023.08.609 PubMed DOI

Canonica GW, Blasi F, Carpagnano GE, et al. Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: a Delphi Consensus. J Allergy Clin Immunol Pract. 2023;11(12):3629–3637. doi:10.1016/j.jaip.2023.07.041 PubMed DOI

McDowell PJ, McDowell R, Busby J, et al. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023;62(6):2300819. doi:10.1183/13993003.00819-2023 PubMed DOI PMC

Menzies-Gow A, Hoyte FL, Price DB, et al. Clinical Remission in Severe Asthma: a Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther. 2022;39(5):2065–2084. doi:10.1007/s12325-022-02098-1 PubMed DOI PMC

Jackson D, Pelaia G, Padilla-Galo A, et al. Asthma Clinical Remission with Benralizumab in an Integrated Analysis of the Real-World XALOC-1 Study. J Allergy Clin Immunol. 2023;151(2):AB13. doi:10.1016/j.jaci.2022.12.045 DOI

Carstens D, Ojeranti D, Chung Y, Chan KA, Dhopeshwarkar N. A real-world analysis of key asthma remission components in patients treated with benralizumab: the ZEPHYR-4 study. J Allergy Clin Immunol. 2024;153(2):AB99. doi:10.1016/j.jaci.2023.11.325 DOI

Frix AN, Heaney LG, Dahlén B, et al. Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study. ERJ Open Res. 2022;8(4):00273–2022. doi:10.1183/23120541.00273-2022 PubMed DOI PMC

Ledford DK, Soong W, Carr W, et al. Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study results. Ann Allergy Asthma Immunol. 2023;131(5):598–605.e3. doi:10.1016/j.anai.2023.07.017 PubMed DOI

Eger K, Paroczai D, Bacon A, et al. The effect of the COVID-19 pandemic on severe asthma care in Europe: will care change for good? ERJ Open Res. 2022;8(2):00065–2022. doi:10.1183/23120541.00065-2022 PubMed DOI PMC

Bloom CI. COVID-19 pandemic and asthma: what did we learn? Respirology. 2023;28(7):603–614. doi:10.1111/resp.14515 PubMed DOI